Neovasc has raised $118.1M in total. We talk with Fred Colen, its CEO.
PetaCrunch: How would you describe Neovasc in a single tweet?
Fred Colen: We are committed to bringing novel therapeutic Devices to patients with unmet medical needs in Cardiology.
PC: How did it all start and why?
FC: It started by specializing in processing and providing tissue based leaflets for minimally invasive heart valve replacement devices, because there was a large unmet need for making such critical components available.
PC: What have you achieved so far?
FC: We have a first class, highly dedicated team, with 2 amazing products in the pipeline: the Reducer (currently CE marked), a unique device to treat remaining patients with refractory Angina (patients who have exhausted all other available treatment options and continue to have debilitating chest pain) and the Tiara, a minimally invasive Mitral valve replacement device to treat severe mitral regurgitation.
PC: How will you use your recent funding round?
FC: To continue our Tiara Clinical studies and our Reducer post market study, as well as to continue to develop commercialization of the Reducer in Europe and to establish the Reducer path to the US market.
PC: What do you plan to achieve in the next 2-3 years?
FC: To achieve CE Mark for the Tiara valve in Europe, to develop the trans-femoral approach for Tiara, to establish meaningful Reducer revenue in Europe, and to introduce the Reducer into the US market.
